Corcept Therapeutics Inc (CORT) stock
CORTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 11/30328% above fair value
$67.79−2.28 (-3.25%)
Close on Nov 18, 2026Market cap $7.33BP/E 161.4Yield –
Corcept Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Corcept Therapeutics's operating income for the twelve months ending Jun 30, 2026 was $6.41M, down 93.7% year over year. For fiscal 2025 it was $44.80M, down 67.3% from the year before. The highest annual figure on record is $136.95M in fiscal 2024.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $44.80M | -67.3% |
| FY2024 | Dec 31, 2024 | $136.95M | +27.7% |
| FY2023 | Dec 31, 2023 | $107.28M | -4.8% |
| FY2022 | Dec 31, 2022 | $112.63M | -9.5% |
| FY2021 | Dec 31, 2021 | $124.48M | -2.9% |
| FY2020 | Dec 31, 2020 | $128.20M | +14.9% |
| FY2019 | Dec 31, 2019 | $111.61M | +24.7% |
| FY2018 | Dec 31, 2018 | $89.50M | +69.3% |
| FY2017 | Dec 31, 2017 | $52.86M | +419.3% |
| FY2016 | Dec 31, 2016 | $10.18M | – |
| FY2015 | Dec 31, 2015 | -$3.44M | – |
| FY2014 | Dec 31, 2014 | -$27.62M | – |
| FY2013 | Dec 31, 2013 | -$41.50M | – |
| FY2012 | Dec 31, 2012 | -$36.27M | – |
| FY2011 | Dec 31, 2011 | -$32.33M | – |
| FY2010 | Dec 31, 2010 | -$27.44M | – |
| FY2009 | Dec 31, 2009 | -$20.25M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $41.30M | +54.8% |
| Q1 FY2026 | Mar 31, 2026 | -$49.60M | -1552.0% |
| Q4 FY2025 | Dec 31, 2025 | $4.49M | -82.2% |
| Q3 FY2025 | Sep 30, 2025 | $10.22M | -78.1% |
| Q2 FY2025 | Jun 30, 2025 | $26.68M | -25.1% |
| Q1 FY2025 | Mar 31, 2025 | $3.42M | -88.4% |
| Q4 FY2024 | Dec 31, 2024 | $25.26M | -20.2% |
| Q3 FY2024 | Sep 30, 2024 | $46.60M | +49.5% |
| Q2 FY2024 | Jun 30, 2024 | $35.59M | +20.3% |
| Q1 FY2024 | Mar 31, 2024 | $29.50M | +98.6% |
| Q4 FY2023 | Dec 31, 2023 | $31.67M | +40.8% |
| Q3 FY2023 | Sep 30, 2023 | $31.18M | -2.4% |
| Q2 FY2023 | Jun 30, 2023 | $29.58M | -5.9% |
| Q1 FY2023 | Mar 31, 2023 | $14.85M | -44.5% |
| Q4 FY2022 | Dec 31, 2022 | $22.50M | -38.6% |
| Q3 FY2022 | Sep 30, 2022 | $31.93M | -11.9% |
| Q2 FY2022 | Jun 30, 2022 | $31.43M | -1.6% |
| Q1 FY2022 | Mar 31, 2022 | $26.77M | +36.3% |
| Q4 FY2021 | Dec 31, 2021 | $36.66M | +20.2% |
| Q3 FY2021 | Sep 30, 2021 | $36.23M | +46.6% |
| Q2 FY2021 | Jun 30, 2021 | $31.94M | -9.4% |
| Q1 FY2021 | Mar 31, 2021 | $19.64M | -47.9% |
| Q4 FY2020 | Dec 31, 2020 | $30.51M | -12.9% |
| Q3 FY2020 | Sep 30, 2020 | $24.72M | -25.1% |
| Q2 FY2020 | Jun 30, 2020 | $35.26M | +43.1% |
| Q1 FY2020 | Mar 31, 2020 | $37.71M | +98.9% |
| Q4 FY2019 | Dec 31, 2019 | $35.02M | +40.6% |
| Q3 FY2019 | Sep 30, 2019 | $33.00M | +43.7% |
| Q2 FY2019 | Jun 30, 2019 | $24.63M | +19.4% |
| Q1 FY2019 | Mar 31, 2019 | $18.96M | -9.7% |
| Q4 FY2018 | Dec 31, 2018 | $24.90M | +14.8% |
| Q3 FY2018 | Sep 30, 2018 | $22.97M | +68.6% |
| Q2 FY2018 | Jun 30, 2018 | $20.63M | +61.3% |
| Q1 FY2018 | Mar 31, 2018 | $21.00M | +342.9% |
| Q4 FY2017 | Dec 31, 2017 | $21.70M | +333.3% |
| Q3 FY2017 | Sep 30, 2017 | $13.62M | +343.5% |
| Q2 FY2017 | Jun 30, 2017 | $12.80M | – |
| Q1 FY2017 | Mar 31, 2017 | $4.74M | – |
| Q4 FY2016 | Dec 31, 2016 | $5.01M | – |
| Q3 FY2016 | Sep 30, 2016 | $3.07M | – |
See a number that looks wrong?